Outpace Bio: Cell Therapy Company Raises $144 Million (Series B)
By Amit Chowdhry ● Aug 14, 2024
Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors, announced that it had raised $144 million in oversubscribed Series B financing. The Series B funding round brought the total capital raised by Outpace to approximately $200 million. It was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments, and other undisclosed investors. Outpace’s existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, WRF Capital, and Sahsen Ventures, also joined in the round.